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Affinity Chromatography: A Review of
Clinical Applications
David S. Hage
Affinity chromatography is a type of liquid chromatog-
raphy that makes use of biological-like interactions for
the separation and specific analysis of sample compo-
nents. This review describes the basic principles of
affinity chromatography and examines its use in the
testing of clinical samples, with an emphasis on HPLC-
based methods. Some traditional applications of this
approach include the use of boronate, lectin, protein A
or protein G, and immunoaffinity supports for the direct
quantification of solutes. Newer techniques that use
antibody-based columns for on- or off-line sample ex-
traction are examined in detail, as are methods that use
affinity chromatography in combination with other an-
alytical methods, such as reversed-phase liquid chroma-
tography, gas chromatography, and capillary electro-
phoresis. Indirect analyte detection methods are also
described in which immunoaffinity chromatography is
used to perform flow-based immunoassays. Other ap-
plications that are reviewed include affinity-based
chiral separations and the use of affinity chromatogra-
phy for the study of drug or hormone interactions with
binding proteins. Some areas of possible future devel-
opments are then considered, such as tandem affinity
methods and the use of synthetic dyes, immobilized
metal ions, molecular imprints, or aptamers as affinity
ligands for clinical analytes.
© 1999 American Association for Clinical Chemistry
Liquid chromatographic methods, and especially those
based on HPLC, are an important group of techniques in
modern clinical laboratories. Clinical chemists are gener-
ally familiar with the most common forms of liquid
chromatography, including reversed-phase, normal-
phase, size-exclusion, and ion-exchange chromatographic
methods. However, there is another category of liquid
chromatography that is often overlooked by clinical
chemists. This technique, known as “affinity chromatog-
raphy”, is rapidly becoming the separation method of
choice in other biologically related fields such as pharma-
ceutical science and biotechnology. Similar developments
are beginning to occur in clinical laboratories, thus creat-
ing a need for clinical chemists to be aware of this
technique. The goal of this review is to acquaint the reader
with affinity chromatography and to discuss the current
or potential applications of this technique in the field of
clinical chemistry. Although several types of affinity
chromatography will be considered, an emphasis will be
placed on those methods in which affinity columns are
used as part of HPLC systems.
According to the International Union of Pure and
Applied Chemistry (1 ), affinity chromatography is de-
fined as a liquid chromatographic technique that makes
use of a “biological interaction” for the separation and
analysis of specific analytes within a sample. Examples of
these interactions include the binding of an enzyme with
an inhibitor or of an antibody with an antigen. Such
binding processes are used in affinity chromatography by
first obtaining a binding agent, known as the “affinity
ligand”, that selectivity interacts with the desired analyte
and then placing this ligand onto a solid support within a
column. [See Refs. (2, 3) for reviews of supports and
immobilization methods that can be used in making
affinity columns.] Once this immobilized ligand has been
prepared, it can be used for isolation or quantification of
the analyte.
The immobilized ligand is the key factor that deter-
mines the success of any affinity chromatographic
method. As implied by the definition given earlier for
affinity chromatography, most of these ligands are of
biological origin; however, the term “affinity chromatog-
raphy” has also been used throughout the years to de-
scribe some columns that contain selective ligands of
nonbiological origin. Examples of these nonbiological
ligands are boronates, immobilized metal ion complexes,
and synthetic dyes (e.g., triazine-related compounds).
Terms such as “bioaffinity chromatography” and “biospe-
cific adsorption” are occasionally used to specify whether
the affinity ligand is really a biological compound. Re-
gardless of the origin of the ligand, the type of ligand can
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be used to divide affinity techniques into various subcat-
egories, such as lectin, immunoaffinity, dye ligand, and
immobilized metal ion affinity chromatography, to name
a few (2, 3). These and other affinity techniques will be
examined in more detail later.
Another factor that can be used to distinguish between
one affinity method and another is the type of support
used within the column. In “low-performance (or column)
affinity chromatography”, the support usually is a large
diameter, nonrigid gel, such as agarose, dextran, or cellu-
lose. In “high-performance affinity chromatography”
(HPAC),1 the support consists of small, rigid particles
based on silica or synthetic polymers that are capable of
withstanding the flow rates and/or pressures that are
characteristic of HPLC systems (2, 4). Both low- and
high-performance methods have been used in clinical
methods. Low-performance affinity chromatography
commonly is used for sample extraction and pretreatment
because it is relatively easy to set up and inexpensive to
use. However, the better flow and pressure stability of
high-performance supports makes HPAC easier to incor-
porate into instrumental systems, which in turn gives it
better speed and precision for the automated quantifica-
tion of analytes.
Direct Analyte Detection by Affinity Chromatography
An example of the simplest and most common operating
scheme for affinity chromatography is shown in Fig. 1. In
this scheme, the sample of interest is first injected onto the
affinity column under conditions in which the analyte will
bind strongly to the immobilized ligand. This is usually
done at a pH and ionic strength that mimic the natural
environment of the ligand and analyte. Because of the
specificity of the analyte-ligand interaction, other solutes
in the sample tend to have little or no binding to the
ligand and quickly wash from the column. After these
nonretained solutes have been removed, an elution buffer
is applied to dissociate the retained analyte; this com-
monly involves changing the pH or buffer composition of
the mobile phase (to decrease the strength of the analyte-
ligand interaction) or adding a competing agent to the
mobile phase (to displace the analyte from the ligand). As
the analyte elutes, it is then detected or collected for
further use. Later, the initial application buffer is reap-
plied to the system, and the column is allowed to regen-
erate before the next sample injection. The overall result is
a separation that is selective and easy to perform. It is this
feature that makes this format so appealing for solute
purification or for the quantification of sample compo-
nents.
In addition to its simplicity, there are several other
advantages to using the direct detection mode of affinity
chromatography. For example, when this mode is per-
formed on an HPLC system, the precision is generally in
the range of 1–5% and the run times are often as low as
5–6 min per sample (for an example, see Fig. 1) (2, 4, 5).
The greater speed of these systems compared with many
other ligand-based techniques (e.g., traditional immuno-
assays) largely can be attributed to the better mass trans-
fer properties and increased analyte-ligand binding rates
that are produced by the supports used in affinity col-
umns. The precision of this approach is partly the result of
the reproducible sample volumes, flow rates, and column
residence times that are possible with modern HPLC
equipment. Another factor that leads to the good preci-
sion in HPLC-based affinity methods is the reduced
batch-to-batch variation, which is the result of using the
same ligand for the analysis of multiple samples and
calibrators. It has been reported in many studies that
several hundred injections can be performed on the same
affinity column, provided that proper elution and regen-
eration conditions have been selected. In some cases, there
have been reports were affinity columns have been used
for .1000 injections with no serious signs of degradation
(2, 5, 6).
One limitation of the direct detection format in affinity
chromatography is that this requires the presence of
enough analyte to allow the measurement of this sub-
stance as it elutes from the affinity column; in HPLC-
based systems this is usually performed by on-line ultra-
violet/visible absorbance or fluorescence detectors. Such
a requirement tends to make the direct detection mode
1 Nonstandard abbreviations: HPAC, high-performance affinity chroma-
tography; HSA, human serum albumin; IAC, immunoaffinity chromatogra-
phy; HPIAC, high-performance IAC; PTH, parathyrin; GC, gas chromatogra-
phy; CE, capillary electrophoresis; RPLC, reversed-phase liquid
chromatography; AChE, acetylcholinesterase; AGP, a1-acid glycoprotein; and
BSA, bovine serum albumin.
Fig. 1. Typical operating scheme for affinity chromatography, as
illustrated by the determination of fibrinogen in human plasma, using
an anti-fibrinogen immobilized antibody column and HPIAC.
The dotted line indicates the times during which the application buffer (pH 7.0)
and elution buffer (pH 2.1) were passed through the column. Adapted with
permission from McConnell and Anderson (49).
594 Hage: Affinity Chromatography
most useful when dealing with intermediate-to-high con-
centration solutes in clinical samples. However, it is also
possible to use direct detection with trace sample compo-
nents if the affinity column is combined with precolumn
sample derivatization and/or more sensitive detection
schemes, such as an off-line immunoassay or a suitable
postcolumn reactor (5 ).
A second potential limitation of the direct detection
mode is that samples and calibrators are analyzed sequen-
tially by the affinity column rather than in batch mode.
This makes the direct detection format most valuable in
situations where low-to-moderate numbers of samples
are being processed and/or fast turnaround times per
sample are desired. It should be noted, however, that
sequential analysis has the advantage of making affinity
chromatography easier to troubleshoot than batch-mode
techniques and easier to determine whether the assay is
operating satisfactorily before patient samples are tested.
boronate affinity chromatography
Affinity methods that use boronic acid or boronates as
ligands are one group of chromatographic techniques that
have been used successfully with clinical samples. This
group of methods, known collectively as “boronate affin-
ity chromatography”, includes one of the earliest reported
quantitative applications of affinity chromatography in
the clinical laboratory—namely, the determination of gly-
cohemoglobin for the assessment of long-term diabetes
management (Fig. 2) (7–15). At a pH above 8, most
boronate derivatives form covalent bonds with com-
pounds that contain cis-diol groups in their structure.
Because sugars such as glucose possess cis-diol groups,
boronates are valuable for resolving glycoproteins (e.g.,
glycohemoglobin) from non-glycoproteins (e.g., normal
hemoglobin).
The first use of a boronate affinity column for the
determination of glycohemoglobin was by Mallia et al. (8 )
in 1981, where a low-performance agarose gel was used as
the support and absorbance detection at 414 nm was used
to quantify the retained and nonretained hemoglobin
fractions in human hemolysate samples. Elution was
performed by passing through the column a soluble
diol-containing agent (i.e., sorbitol) that displaced the
retained glycohemoglobin from the column; alternatively,
a decrease in mobile phase pH could also be used for
elution (9 ). After the initial report by Mallia et al., similar
low-performance methods were reported or evaluated by
other groups (10–13). The same approach has since been
adapted for use in HPAC and HPLC-based systems
(9, 11, 14, 15).
In addition to hemoglobin, it is possible to use bor-
onate columns to look at other types of glycoproteins in
samples. For example, by monitoring the absorbance at
280 nm instead of 410–415 nm, the technique used for
glycohemoglobin can easily be modified to determine the
relative amount of all glycated proteins in a sample (14 ).
Alternatively, a particular type of glycoprotein can be
examined by combining a boronic acid column with a
detection method that is specific for the protein of interest,
such as is done by using absorbance measurements at
410–415 nm for the quantification of glycohemoglobin.
Examples of this later approach include the use of boronic
acid columns followed by an immunoassay for the detec-
tion of glycated albumin in serum and urine (16 ) or for
the determination of glycated apolipoprotein B in serum
(17 ).
lectin affinity chromatography
Lectins are another class of ligands that have been used
for the direct detection of clinical analytes by affinity
chromatography. The lectins are non-immune system
proteins that have the ability to recognize and bind certain
types of carbohydrate residues (18 ). Two lectins that are
often placed into affinity columns are concanavalin A,
which binds to a-d-mannose and a-d-glucose residues,
and wheat germ agglutinin, which binds to d-N-acetyl-
glucosamine. Other lectins that can be used are jacalin and
lectins found in peas, peanuts, or soybeans. These ligands
Fig. 2. Determination of glycohemoglo-
bin (Glc-Hb) by HPAC for 10-mL sam-
ples of diluted whole blood.
Adapted with permission from Singhal and
DeSilva (14).
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commonly are used in the isolation of many carbohy-
drate-containing compounds, such as polysaccharides,
glycoproteins, and glycolipids (2, 3).
One clinical application of lectin affinity chromatogra-
phy has been in the separation and analysis of isoen-
zymes. This is illustrated in Fig. 3, where an HPLC
column containing immobilized wheat germ agglutinin
was used to distinguish between the liver- and bone-
derived isoenzymes of alkaline phosphatase in human
serum (19 ). This method showed improved resolution of
the isoenzymes vs a low-performance affinity column (20 )
and gave good correlation for a variety of patient samples
when compared with a solid-phase immunoassay for
alkaline phosphatase (21 ).
A variety of other glycoproteins also have been studied
and quantified by the use of lectin affinity columns. For
example, low-performance columns based on concanava-
lin A have been used to separate apolipoprotein A- and
apolipoprotein B-containing lipoproteins in human
plasma (22 ), to study the microheterogeneity of serum
transferrin during alcoholic liver disease (23 ), and to
characterize the carbohydrate structure of follicle-stimu-
lating hormone and luteinizing hormone under various
clinical conditions (24 ). A combination of concanavalin A
and wheat germ agglutinin columns also has been used to
identify changes that occur in asparagine-linked sugars
on human prostatic acid phosphatase during prostate
cancer (25 ).
protein a or protein g affinity chromatography
A third class of ligands that have been used in direct
analyte detection by affinity chromatography are anti-
body-binding proteins such as protein A and protein G.
These are bacterial cell wall proteins produced by Staph-
ylococcus aureus and group G streptococci, respectively
(26–28). These ligands have the ability to bind to the
constant region of many types of immunoglobulins. Pro-
tein A and protein G bind most strongly to immunoglobu-
lins at or near neutral pH, but readily dissociate from
these solutes when placed in a buffer with a lower pH.
These two ligands differ in their ability to bind to anti-
bodies from different species and classes (3, 26, 29); for
example, human IgG3 binds much more strongly to
protein G than protein A, and human IgM shows no
binding to protein G but does interact weakly with
protein A (3 ). A recombinant protein known as protein
A/G, which blends the activities of these ligands, also is
available for use in affinity columns (3, 30).
The ability of protein A and protein G to bind to
antibodies make these good ligands for the analysis of
immunoglobulins, especially IgG-class antibodies, in hu-
mans. The first clinical uses of these ligands in an HPLC
system were methods based on immobilized protein A for
the analysis of IgG in serum samples (31, 32). A similar
method for the determination of IgG in serum has been
developed based on high-performance protein G columns
(33 ). Yet another study used a combination of two affinity
columns, one containing immobilized protein A and the
other containing anti-human serum albumin (HSA) anti-
bodies, for the simultaneous analysis of IgG and albumin
in serum for the determination of albumin/IgG ratios
(Fig. 4) (34 ). An additional application of protein A and
protein G has been as secondary ligands for the adsorp-
tion of antibodies onto supports to be used in immunoaf-
finity chromatography, as discussed in the following
section. This particular method can be used when high
antibody activities are needed or if it is desirable to
Fig. 3. Determination of liver and
bone-derived isoenzymes of alkaline
phosphatase by HPAC, using an im-
mobilized wheat germ agglutinin col-
umn for 50-mL injections of serum
from patients with liver (A) or bone (B)
disease, and healthy individuals (C).
The peaks at 5.6–5.7 min and 15.0–15.2
min are produced by the liver- and bone-
derived isoenzymes, respectively. Adapted
with permission from Gonchoroff et al.
(21).
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replace the antibodies in the affinity column frequently
(5, 6, 35).
immunoaffinity chromatography
Of all the types of affinity chromatography, those that use
antibodies or antibody fragments as ligands make up the
largest and most diverse group of affinity methods in
clinical testing. This is a combined result of the specificity
of antibodies and the relative ease with which they can be
obtained to a wide variety of analytes. The term “immu-
noaffinity chromatography” (IAC) is used for an affinity
chromatographic method in which the stationary phase
consists of an antibody or antibody-related reagent
(5, 35). When such a technique is performed as part of an
HPLC system, the resulting method can be referred to as
“high-performance immunoaffinity chromatography”
(HPIAC) (5, 35).
Several examples of direct analyte detection by HPLC-
based IAC are described in Ref. (5 ). Some clinical appli-
cations that have been reported include methods devel-
oped for anti-idiotypic antibodies (36, 37), glucose-
containing tetrasaccharides (38, 39), granulocyte colony-
stimulating factor (40 ), HSA (34, 41), IgG (42 ),
immunoglobulin E (43 ), interferon (44, 45), tumor necro-
sis factor-a (45 ), interleukins (45, 46), b2-microglobulin
(47 ), and transferrin (48 ). One such example (i.e., the
determination of fibrinogen in human plasma) is illus-
trated in Fig. 1 (49 ). In this particular case, the amount of
fibrinogen in the retained peak was determined by the
measurement of its absorbance at 280 nm. The sample was
a 20-mL aliquot of plasma diluted 1:10. The retained peak
appeared at 6 min, and the time between sample injec-
tions was 15 min, which included 9 min for column
reequilibration (49 ).
Both large and small analytes can be determined by the
use of direct detection in IAC. Furthermore, it is possible
to utilize immunoaffinity columns either separately or in
combination with other affinity columns. This was dem-
onstrated in the previous section in the discussion of the
dual-column immunoaffinity/protein A method for the
analysis of HSA and IgG in serum (34 ). A similar ap-
proach recently has been used with fluorescent labeled
samples and up to 10 separate immunoaffinity columns
connected in series for the simultaneous determination of
various cytokines in clinical samples (Fig. 5) (45 ). In
theory, this multicolumn format could be used with even
larger numbers of compounds and with other combina-
tions of analytes. The fact that a single sample aliquot is
required for all of the columns makes this technique
appealing in situations where only a limited amount of a
patient’s sample may be available for analysis.
When used as part of an HPLC system, the direct
detection of analytes as they elute from immunoaffinity
columns usually involves monitoring their ultraviolet/
visible absorbance. However, special methods for the
detection of low-concentration analytes have also been
devised that use precolumn derivatization to place fluo-
rescent tags (40, 45, 46) or radiolabels (39 ) onto sample
solutes before injection. Alternatively, the column eluate
can be collected in fractions and later analyzed by an
immunoassay (43, 47) or receptor assay (46 ) that is spe-
cific for the species of interest. In addition, specialized
methods can be combined with IAC to monitor com-
pounds that elute in the nonretained fraction of the
sample. This latter approach was used recently in a
method that combined an HPIAC column and flow injec-
tion analysis for the determination of urinary albumin/
creatinine ratios. This technique used an anti-albumin
immunoaffinity column for the capture and detection of
HSA and a Jaffe´-based colorimetric reactor for the quan-
tification of creatinine in the portion of the sample that
was not bound by the antibody column (30 ). This is yet
Fig. 4. Chromatograms (top) and valve switching system (bottom) for
10-mL injections of an HSA calibrator (a), an IgG calibrator (b), a
mixture of HSA and IgG (c), and a 1:5 dilution of serum (d) on a dual
column HPAC system containing anti-HSA antibodies and immobilized
protein A.
The solid lines within the six-port valve shown at the bottom represent the
configuration of the system during sample injection and later elution of IgG from
the protein A column; the dashed lines show the position of the valve during the
elution of albumin from the anti-HSA column. Adapted with permission from Hage
and Walters (34).
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Fig. 5. Diagram of a recycling immunoaffinity system for the determination of multiple analytes during sample application (a) and stepwise analyte
elution (b) from each column in the system; and chromatogram (c) showing results obtained for the analysis of a calibration mixture.
In (c), the sample contains (left to right) interleukin-1 (IL-1), IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, tumor necrosis factor-a, and g-interferon, each present at a
concentration of 100 ng/L in the injected sample. The arrows in (c) indicate the times at which the valve configuration was changed for stepwise analyte elution.
Adapted with permission from Phillips and Krum (45).
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another approach that could be useful when only small
amounts of sample are available and information on
several clinical analytes is desired.
columns based on miscellaneous ligands
In addition to the ligands that have been mentioned
already, several other types of ligands have also been
used for the direct detection of clinical analytes by affinity
chromatography. For example, an immobilized heparin
column has been used for the determination of antithrom-
bin III in human plasma (50, 51). S-Octylglutathione has
been reported as a ligand for the separation and analysis
of glutathione S-transferase isoenzymes in human lung
and liver samples (52, 53). And finally, immobilized p-
aminobenzamidine has been used for the separation of
human plasminogen species, with the addition of an
immobilized urokinase column for on-line detection (54 ).
Chromatographic Immunoassays
One relatively new area of affinity chromatography that
has received increasing attention in recent years has been
the use of both low- and high-performance immunoaffin-
ity columns to perform various types of immunoassays.
Such an approach is known as a “chromatographic (or
flow-injection) immunoassay”. This technique has been
reviewed recently (5, 6, 55–58). This format is particularly
valuable in the determination of trace analytes that by
themselves may not produce a readily detectable signal
when analyzed directly by affinity chromatography. This
problem is overcome in chromatographic immunoassays
by the use of a labeled antibody or analyte analog that can
be used for indirect analyte detection.
Many of the same labels that have been used in
traditional immunoassays have also been used within
chromatographic-based immunoassays. For example, en-
zyme labels such as horseradish peroxidase, alkaline
phosphatase, and glucose oxidase have all been used in
such methods. Other labels that have been reported
include fluorescent tags such as fluorescein, Texas red, or
lucifer yellow; chemiluminescent labels based on acri-
dinium esters; and liposomes impregnated with fluores-
cent dye molecules (5 ). The detection of these labels
generally is performed on line as they elute in the nonre-
tained or retained peaks of the immunoaffinity column;
however, fraction collection and off-line detection can also
be used when required.
competitive binding immunoassays
There are several different methods for performing chro-
matographic immunoassays, but the most common
method uses a competitive binding format. The easiest
approach is to mix the sample with a labeled analyte
analog (i.e., the label) and to inject the mixture simulta-
neously onto an immunoaffinity column that contains a
relatively small amount of antibody. This format, known
as a “simultaneous injection competitive binding immu-
noassay”, is the most common approach for chromato-
graphic immunoassays. A specific example of this method
is shown in Fig. 6, in which theophylline was measured in
serum by a flow-injection competitive binding immuno-
assay that used carboxyfluorescein-impregnated lipo-
somes as the label. The injected samples contained 50 mL
of serum diluted 1:100 and combined in a 1:2 ratio with a
working solution of the label. The total cycle time between
samples was 16 min, and good correlation was noted vs a
fluorescence polarization immunoassay (59 ). Other clini-
cal analytes that have been measured by simultaneous
injection competitive binding immunoassays include hu-
man chorionic gonadotropin (60 ), thyroid-stimulating
hormone (60 ), HSA (61 ), IgG (62, 63), testosterone (64 ),
and transferrin (61, 65); additional studies with theophyl-
line have also been reported (66–69).
An alternative format that has been explored for clin-
ical testing involves the application of only sample to the
immunoaffinity column, followed later by a separate
injection of the label. This method is known as a “sequen-
tial injection competitive binding immunoassay” (61, 70).
Fig. 6. Scheme for a theophylline flow-based simultaneous injection
competitive binding immunoassay, using a label that consists of
liposomes impregnated with carboxyfluorescein as a fluorescent
marker.
Reproduced with permission from Locascio-Brown et al. (59).
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One advantage of the sequential injection approach is that
even an unlabeled preparation of analyte potentially can
be used as the label, provided that this species produces a
sufficient signal for detection; this method is particularly
useful for complex samples that contain analytes at mod-
erate-to-high concentrations in complex mixtures. An-
other advantage of this technique over the simultaneous
injection format is that there are no matrix interferences
present during detection of the label because it is never in
contact with the actual sample. However, the sequential
injection method does require an additional step vs the
simultaneous injection method for the separate applica-
tion of label to the immunoaffinity column. One strength
of both the simultaneous and sequential injection compet-
itive binding methods is that they can be used equally
well for either small or large analytes.
sandwich immunoassays
The sandwich immunoassay, or two-site immunometric
assay, can also be performed as part of an affinity chro-
matographic system (71–74). In this technique, two dif-
ferent types of antibodies that bind to the analyte of
interest are used. The first of these two antibodies is
attached to a chromatographic support and is used to
extract the analyte from samples. The second antibody
contains an easily measured tag and is added in solution
to the analyte either before or after sample injection; this
second antibody serves to place a label onto the analyte,
thus allowing the amount of analyte on the immunoaffin-
ity support to be quantified as it and the label are eluted
from the column.
One clinical application in which a chromatographic
sandwich immunoassay has been used is in the determi-
nation of intact parathyrin (PTH) in plasma (73, 74). Fig. 7
shows a typical calibration curve and correlation plot for
this technique. This particular method involved incuba-
tion of plasma samples combined in a 2:1 ratio with a
working solution of anti-(1–34 PTH) acridinium ester-
labeled antibodies for 1 h. After the incubation, a 100-mL
aliquot of this mixture was injected onto an immunoaf-
finity column containing anti-(44–68 PTH) antibodies,
thus producing formation of sandwich immune complex
within the column. The amount of retained PTH was then
determined by examination of the signal produced by the
labeled antibodies as they were eluted at pH 3.0 and
passed through a postcolumn chemiluminescence reactor.
The total time per sample injection was 6.0–6.5 min, and
the limit of detection was 0.2 pmol/L PTH (73, 74). Other
analytes that have been examined by chromatographic
sandwich immunoassays are some antigen-specific anti-
bodies (71 ) and IgG (72 ).
Like its traditional solid-phase counterpart, an impor-
tant advantage of the chromatographic sandwich immu-
noassay is that it produces a signal for the bound label
that is directly proportional to the amount of injected
analyte (Fig. 7a). The use of two types of antibodies in a
sandwich immunoassay gives this technique higher selec-
tivity than chromatographic-based competitive binding
immunoassays. The main disadvantage of the chromato-
graphic sandwich immunoassay is that it can be used only
for analytes such as large peptides or proteins that are
large enough to bind simultaneously to two separate
antibodies.
one-site immunometric assays
This is the third format that has been used to automate
immunoassays by affinity chromatography. This ap-
proach has been used in determining such agents as
thyroxine (55 ) and a-(difluoromethyl)ornithine (75 ). In
this technique, the sample first is incubated with a known
excess of labeled antibodies or Fab fragments that are
specific for the analyte of interest. After binding between
the analyte and antibodies has occurred, this mixture is
applied to a column that contains an immobilized analog
of the analyte. This column serves to extract any antibod-
ies or Fab fragments that are not bound to the original
analyte. Meanwhile, those antibodies or Fab fragments
Fig. 7. Calibration curve (a) and correlation plot (b) vs a manual
immunochemiluminometric assay (ICMA) for the determination of
intact PTH in human plasma by use of a sandwich immunoassay
format in HPIAC with chemiluminescence detection (HPIAC/CL).
The inset in (a) shows an expanded view of the lower end of the calibration curve.
Reproduced with permission from Hage et al. (75).
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that are bound to analyte from the sample will pass
through the column in the nonretained peak, which is
then detected and used for analyte quantification. Like the
chromatographic competitive binding immunoassays,
this method is able to detect both small and large solutes.
However, like a chromatographic sandwich immunoas-
say, it also gives a signal for the nonretained label that is
directly proportional to the amount of analyte in the
original sample. One disadvantage of this approach is that
relatively pure and highly active labeled antibodies/Fab
fragments must be used to provide a low background
signal.
Affinity Extraction
The technique of “affinity extraction” refers to the use of
affinity chromatography for the isolation of a specific
solute or group of solutes from a sample before their
determination by a second analytical method. This uses
the same general operating scheme as other types of
affinity chromatography, but now involves combining the
affinity column either off-line or on-line with some other
method for the actual quantification of analytes. Affinity
extraction represents one of the most common uses of
affinity chromatography in chemical analysis. This section
will examine some applications of affinity extraction,
including both off-line methods and those that involve the
on-line coupling of affinity columns with techniques such
as HPLC, gas chromatography (GC), or capillary electro-
phoresis (CE).
off-line affinity extraction
Off-line extraction is the easiest method for combining an
affinity column with another analytical technique. This
approach typically involves the use of an affinity ligand
that is immobilized onto a low-performance support (e.g.,
activated agarose) that is packed into a small disposable
syringe or solid-phase extraction cartridge. After the
affinity column is conditioned with the necessary appli-
cation buffer or conditioning solvents, the sample is
applied and nonbound sample components are washed
off of the packing, as shown in Fig. 1. An elution buffer is
then applied, and the analyte is collected as it elutes from
the column. In some cases, this eluted fraction is analyzed
directly by a second technique, but in most situations the
collected fraction is first dried and reconstituted in a
solvent that is compatible with the method to be used for
quantification. If needed, the collected solute fraction may
also be derivatized before it is examined by other tech-
niques to obtain improved detection or more appropriate
physical properties (e.g., an increase in solute volatility
before separation and analysis by GC).
The most common ligands in affinity extraction are
antibodies, with the terms “immunoextraction” or “im-
munoaffinity extraction” often being used to refer to this
particular extraction technique. Sample preparation by
off-line immunoextraction has been the subject of several
recent reviews (5, 76–79), most of which have empha-
sized its applications in the area of drug residue analysis.
Examples involving human samples include the use of
immunoextraction before reversed-phase liquid chroma-
tography (RPLC) in the determination of albuterol in
plasma (80 ), human chorionic gonadotropin in urine (81 ),
and ochratoxin A in human serum, plasma, or milk (82 ).
Off-line immunoextraction also has been used for sample
clean-up before analysis by GC or GC–mass spectrometry
in the determination of prostaglandins and thromboxanes
(83–86) or alkylated DNA adducts (87, 88) in human
urine. The same approaches have been used in several
animal studies involving off-line immunoextraction and
RPLC or GC for the detection of alkylated DNA adducts
in DNA extracts from rats (89 ), chloramphenicol in urine
and tissue samples from pigs (90 ), dexamethasone and
flumethasone in equine urine (91, 92), ivermectin and
avermectin in sheep serum (93 ), and estrogens (94, 95),
nortestosterone (96 ), or trenbolone (97 ) in bovine urine
and bile samples.
Although antibodies are the most popular ligands in
off-line affinity extraction, they are not the only ligands
used for this approach. For example, sample extraction by
an organomercurial agarose column followed by RPLC
analysis has been used for the assessment of urinary
2-thioxothiazolidine-4-carboxylic acid, a proposed indica-
tor of environmental exposure to carbon disulfide (98 ).
Off-line boronic acid columns similarly have been used
for the reversed-phase analysis of modified nucleosides in
patients with gastrointestinal cancer (99 ) and in the
purification of human platelet glycocalicin before analysis
by anion-exchange HPLC (100). A method based on a
wheat germ agglutinin extraction column combined with
high-performance anion-exchange chromatography has
been reported as a means to purify and analyze angio-
tensinase A and aminopeptidase M in human urine and
kidney samples (101). Another application of affinity
extraction is in the removal of specific interferences from
samples. Examples include the use of protein A and
anti-mouse immunoglobulin supports for the removal of
human anti-mouse antibodies before the analysis of a
sample by immunoassay (102) and with the use of anti-
human immunoglobulin IAC or protein A supports to
selectively adsorb enzyme-immune complexes (i.e., mac-
roenzymes) from patient samples (103).
It should always be kept in mind when using affinity
extraction that many ligands (even antibodies) will show
some binding or cross-reactivity with solutes that are
closely related to the desired analyte in structure. Each
affinity extraction method should be evaluated for such
cross-reactivity by the use of binding and interference
studies with any solutes or metabolites that are similar to
the analyte and that may be present in the samples of
interest. However, even if several solutes do bind to the
same extraction column, this does not present a problem
as long as the analyte can be resolved or discriminated
from these other compounds by the method that is used
for quantification. In many cases, this can even be used to
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an advantage because it allows several species in the same
class of compounds to be determined in a single analytical
run. For example, the ability of antibodies to cross-react
with a parent compound and related agents or metabo-
lites has been used for the development of immunoextrac-
tion methods for 17a- and 17b-trenbolone (97 ), 17a- and
17b-nortestosterone (96 ), and diethylstilbestrol, dienes-
trol, and hexestrol (94 ). This idea can be taken one step
further by the use of multiple types of antibodies in the
same column. This has been used in the HPLC analysis of
testosterone, nortestosterone, methyltestosterone, trenbo-
lone, zeranol, estradiol, diethylstilbestrol, and related
compounds in urine, where samples were extracted off-
line with an affinity column that contained seven different
types of immobilized antibodies (76 ).
One advantage of off-line affinity extraction is that the
samples collected from the extraction column can be
derivatized readily or placed into a different solvent
between the sample purification and quantification steps.
This advantage is particularly important when affinity
extraction is combined with GC, where it is desirable to
remove any water from the collected sample before injec-
tion onto the GC system and solute derivatization is often
required to improve solute volatility or detection. An-
other advantage of off-line affinity extraction is that it is
relatively easy to set up once an appropriate ligand
preparation has been selected or obtained. The cost of an
affinity extraction cartridge is typically much higher than
for conventional solid-phase extraction; however, this
difference can be minimized by the careful selection of
application and elution conditions so that the same affin-
ity cartridge can be used for multiple samples (76 ).
on-line affinity extraction
The direct coupling of affinity extraction with other
analytical methods is yet another area that has been the
subject of increasing research. The use of immunoextrac-
tion columns as part of HPLC systems has been of
particular interest (5, 6). The relative ease with which
immunoaffinity columns can be incorporated into an
HPLC system makes this appealing as a means for auto-
mating immunoextraction methods and for reducing the
time required for sample pretreatment. In addition, the
relatively high precision of HPLC pumps and injection
systems provides on-line immunoextraction with better
precision than off-line extraction methods, because the
on-line approach has more tightly controlled sample
application and elution conditions.
Clinical applications of on-line immunoextraction in
HPLC have been developed for such analytes as a1-
antitrypsin (104), cortisol (105), digoxin (106), estrogens
(107, 108), human epidermal growth factor (109), lysergic
acid diethylamide, lysergic acid diethylamide analogs
and metabolites (110, 111), phenytoin (112), propranolol
(110), D9-tetrahydrocannabinol (113), and transferrin
(104, 114). Additional details on these methods are pro-
vided in Ref. (5 ). All of these particular examples have
used immunoaffinity columns combined with standard
analytical columns for RPLC; however, there have also
been reports from the field of biotechnology that have
described the use of on-line immunoextraction with size
exclusion (115) or ion-exchange chromatography
(116, 117).
One reason for the large number of reports involving
the combination of on-line immunoextraction with RPLC
undoubtedly has to do with the popularity of RPLC in
routine analytical separations. Another, more fundamen-
tal, reason arises from the fact that the elution buffer for
an immunoaffinity column is an aqueous solvent that
generally contains little or no organic modifier, a feature
that makes this same buffer act as a weak mobile phase for
RPLC. This means that as a solute elutes from an anti-
body-based column, it will tend to have strong retention
on any on-line reversed-phase support, thus leading to
analyte reconcentration. This effect is valuable for ana-
lytes that desorb slowly from immobilized antibody col-
umns and thus are difficult to analyze by the direct
detection mode of affinity chromatography.
One common format for on-line immunoextraction in
RPLC (Fig. 8) involves injecting the sample onto an
immunoaffinity extraction column, with the nonretained
components being flushed into a waste container. The
immunoaffinity column is then switched on-line with a
RPLC precolumn, and an elution buffer is applied to the
antibody support to dissociate any retained analyte. As
these analytes elute, they are captured and reconcentrated
at the head of the RPLC precolumn. After all solutes have
left the immunoaffinity column, this column is then
switched back off-line and regenerated by washing with
the initial application buffer. Meanwhile, the RPLC pre-
column is placed on-line with a larger analytical RPLC
column, and both are developed with an isocratic or
gradient elution scheme involving the application of a
solvent with an increased organic modifier content. This
causes analytes at the head of the RPLC precolumn to
move through the analytical column and to be separated
on the basis of their differences in polarity. As these
solutes elute, they are monitored and quantified through
the use of a flow-through detector.
Other ligands besides antibodies, particularly borona-
tes, have been shown to be valuable in performing on-line
affinity extraction with HPLC. Examples include several
separation methods in which boronate columns have been
combined with HPLC columns for the clinical analysis of
catechol-related compounds such as epinephrine, norepi-
nephrine, and dopamine (118–120), dihydroxyphenylala-
nine (121), dihydroxyphenylacetic acid (121, 122), 5-S-
cysteinyldopa (123), and vanillylmandelic acid (124). This
same approach has been adapted for profiling (125) and
quantifying ribonucleotides in urine (126, 127) and serum
(127).
Although not as common as on-line extraction in
HPLC, there has been some work investigating the use of
affinity extraction coupled directly with GC for the deter-
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mination of b-19-nortestosterone and related steroids in
urine (128). In this case, a RPLC precolumn was again
used to capture and reconcentrate retained analytes as
they eluted from an immunoaffinity extraction column.
However, this RPLC precolumn also now served to re-
move any water from the analytes and to place them into
a volatile organic solvent (ethyl acetate, which was used
as the elution mobile phase). A portion of the analytes that
eluted from the RPLC precolumn was then passed into
the injection gap of a GC system. Once the solute/organic
solvent plug had entered the GC system, a temperature
program was initiated for solute separation. One advan-
tage of this approach (and also of immunoextraction/
HPLC) is that large volumes of sample can be applied to
the immunoaffinity column, thus providing low detection
limits. The main disadvantage of on-line immunoextrac-
tion in GC is the greater complexity of this method vs
off-line immunoextraction or on-line immunoextraction/
HPLC.
Several recent studies have considered the additional
possibility of combining on-line immunoextraction with
CE. For example, immunoextraction based on immobi-
lized Fab fragments was used to extract and concentrate
tear samples for the CE analysis of cyclosporin A and its
metabolites in samples from corneal transplant patients
(Fig. 9) (129). In another study, antibodies were covalently
immobilized in microcapillary bundles or in laser-drilled
glass rods that were then connected to a CE capillary for
the on-line immunoextraction and detection of immuno-
globulin E in serum (130). Finally, a capillary packed with
a protein G chromatographic support has been used to
adsorb antibodies for the extraction and concentration of
insulin from serum before quantification by CE (131).
Postcolumn Affinity Detection
Yet another way in which affinity columns can be used is
for monitoring the elution of specific solutes from other
chromatographic columns. This involves the use of a
postcolumn reactor and an affinity column attached to the
exit of an analytical HPLC column. A large number of
affinity ligands can be used for this purpose. One specific
example is the reported use of anion-exchange chroma-
tography followed by an HPLC boronate column for the
determination of glycated albumin in serum samples
(132). Another example is the recent use of immobilized
Fig. 8. Scheme for coupling on-line immunoextrac-
tion by HPIAC with compound separation and anal-
ysis by RPLC.
Reproduced with permission from Hage (55).
Fig. 9. Analysis of cyclosporin A in tear samples by routine CE (a) and
immunoextraction coupled on-line with CE (b).
CyA, cyclosporin A; peaks 1–4 in panel b represent various cyclosporin A
metabolites. Adapted with permission from Phillips and Chmielinska (129).
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receptors for the detection of bioactive interleukin-2 as it
eluted from an anti-interleukin immunoaffinity HPLC
column (47 ). As in many other affinity methods, most
research in the area of postcolumn affinity detection has
used immobilized antibody (or immobilized antigen) col-
umns. This has given rise to a specific type of detection
scheme known as “postcolumn immunodetection”
(5, 133).
The direct detection mode of affinity chromatography
represents the simplest approach for postcolumn quanti-
fication of an analyte, provided that the solute is capable
of generating a sufficiently strong signal for detection.
One example of this approach involved the use of size
exclusion chromatography and postcolumn immunode-
tection for the analysis of acetylcholinesterase (AChE) in
amniotic fluid (134). The method in this report used an
immunoaffinity column containing anti-AChE antibodies
to capture AChE as it eluted from the analytical column.
After the AChE was adsorbed to the immunoaffinity
column, a substrate solution for AChE was passed
through the column, and the resulting colored product
was detected by an on-line absorbance detector.
Other formats also are possible for postcolumn immu-
nodetection, including techniques based on competitive
binding immunoassays (133, 135) and sandwich immuno-
assays (136). However, the one-site immunometric assay
is the most common format for immunodetection, and it is
the only additional approach that has been used previ-
ously in clinical applications. The basic operation of this
format involves taking the eluate from the HPLC analyt-
ical column and combining this with a solution of labeled
antibodies or Fab fragments that bind to the analyte of
interest. The mixture of column eluate and antibody or
Fab fragments is then allowed to react in a mixing coil and
passed through an immunodetection column that con-
tains an immobilized analog of the analyte. The antibodies
or Fab fragments that are bound to the analyte will pass
through this column and onto the detector, where they
will provide a signal that is proportional to the amount of
bound analyte. If desired, the immunodetection column
can be washed later with an eluting solvent to dissociate
the retained antibodies or Fab fragments; but a suffi-
ciently high binding capacity is generally used so that a
reasonably large amount of analytical column eluate can
be analyzed before the immunodetection column must be
regenerated.
One-site immunometric detection originally was used
to quantify digoxin and digoxigenin as they eluted from a
standard RPLC column by the use of fluorescein-labeled
Fab fragments (raised against digoxigenin) and an immo-
bilized digoxin support in the postcolumn detection sys-
tem (137). This method was then used to successfully
monitor both digoxin and its metabolites in plasma and
urine samples (137). The same general system was later
used along with a restricted-access RPLC column to
monitor digoxin, digoxigenin, and related metabolites in
serum samples (138).
Affinity-based Chiral Separations
Another important application of affinity ligands has
been in the analysis of chiral compounds (139). Because of
pressure from regulatory agencies such as the US Food
and Drug Administration, there has been increasing in-
terest in the pharmaceutical field for methods capable of
discriminating between the individual chiral forms of
drugs (140). This has also touched on the field of clinical
chemistry, where the ability to quantify the different
chiral forms of a drug or its metabolites is increasingly
used in studies of drug metabolism and in therapeutic
monitoring. HPLC methods that include chiral stationary
phases make up one set of tools that have been shown to
be particularly valuable in the quantification and separa-
tion of chiral compounds (139, 141). Because many of the
ligands used in affinity chromatography are inherently
chiral, this makes them logical choices as stationary
phases for such separations.
As will be seen later, various naturally occurring
proteins and carbohydrates have been used as ligands for
chiral separations of clinical analytes (142–161). Other,
synthetic ligands that have also been used for chiral
separations with clinical samples, such as derivatives of
amylose or cellulose and Pirkle-type stationary phases
(162–189), but these other ligands will not be considered
in this present review. Most clinical separations that will
be discussed were performed by routine liquid-liquid or
solid-phase extraction of the sample, with the content of
this extract later being injected onto the chiral column of
interest. However, this is not the only approach that can
be used. In some cases, a chiral column was first used to
resolve the enantiomers of a particular solute, followed by
collection of these fractions and their on-line or off-line
injection onto a second, achiral column for further sepa-
ration and quantification (Fig. 10) (150, 156). Alterna-
tively, an achiral column, such as a reversed- or normal-
phase support, was sometimes used to isolate the
compounds from the sample, and a chiral column was
then used on-line or off-line to resolve the enantiomers in
each peak of interest (151, 152).
protein-based stationary phases
Proteins are one group of affinity ligands that have
received some attention as chiral HPLC stationary phases.
Although all proteins are chiral, only one [a1-acid glyco-
protein (AGP)] has seen any significant use in the analysis
of chiral drugs in clinical samples. AGP (also known as
AAG or orosomucoid) is a human serum protein involved
in the transport of many small solutes throughout the
body. AGP differs from HSA (another drug-binding pro-
tein in serum) in that AGP has a lower isoelectric point
and contains carbohydrate residues as part of its struc-
ture. The lower isoelectric point makes AGP more useful
than serum albumin in binding cationic compounds,
whereas the carbohydrate residues may play a role in
determining the stereoselectivity of the binding properties
of AGP (141). There are many drugs and related solutes
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that have been separated by AGP in human urine, serum,
or plasma. Examples of clinical interest include bunolol
(142), citalopram (143), fenoprofen (144), flurbiprofen
(145), ibuprofen (144, 146), ketamine (147), ketoprofen
(144), methadone (148–150), norketamine (147), norvera-
pamil (151), pindolol (152), thiopentone (153), vamicam-
ide (154), and verapamil (151, 155).
Other proteins that have received some attention in
clinical applications of chiral HPLC are bovine serum
albumin (BSA) and ovomucoid. Ovomucoid is a glycop-
rotein obtained from egg whites that has been shown to
be useful in the separation of cationic solutes (141). BSA is
a member of the serum albumin family, which constitute
most of the protein content of serum in mammals and are
involved in the transport of a wide range of small organic
and inorganic compounds throughout the body, includ-
ing many pharmaceutical agents (190, 191). BSA, and the
related protein HSA, tend to bind best to neutral or
anionic compounds, thus making these proteins comple-
mentary to AGP and ovomucoid in their applications
(139, 141). In clinical work, BSA has been used for the
chiral separation of leucovorin in plasma (156), and
ovomucoid has been used for separating the individual
forms of pentazocine in serum samples (157).
carbohydrate-based stationary phases
One class of natural carbohydrates that can be used as
stereoselective ligands in HPLC are the cyclodextrins
(158–161). These are circular polymers of a-1,4-d-glucose
that are produced through the degradation of starch by
the microorganism Bacillus macerans. The most common
forms of these polymers are a-, b-, and g-cyclodextrin,
which contain six, seven, or eight glucose units, respec-
tively (139, 141). The cone-shaped structure and hydro-
phobic interior cavity of cyclodextrins give them the
ability to form inclusion complexes with numerous small,
aromatic solutes. Furthermore, the well-defined arrange-
ment of hydroxyl groups about the upper and lower faces
of the cyclodextrins provide these agents with the ability
to discriminate between various chiral compounds. Ex-
amples of some clinical applications for cyclodextrins in
HPLC include methods reported for chlorpheniramine
(158), citalopram, desmethylcitalopram, and didesmeth-
ylcitalopram (159), hexobarbital (158), the M1 and M2
metabolites of moguisteine (160), and propranolol (161).
Characterization of Drug- and
Hormone-Protein Interactions
In addition to its applications as a method for quantifying
or isolating specific solutes, affinity chromatography can
also be used in studying the interactions that take place
between biomolecules. Such an approach is known as
“analytical” or “quantitative affinity chromatography”.
This area has been the subject of several past reviews and
has been used to examine a variety of biological systems,
including lectin/sugar, enzyme/inhibitor, protein/pro-
tein, and DNA/protein interactions (2, 192). However,
most work in the clinical arena has focused on the use of
this technique in the study of the binding of drugs or
hormones to serum proteins (193–195). In some instances,
this type of protein binding occurs with general ligands,
such as the interaction of many drugs with HSA or AGP
(196–199). In other cases, this binding is highly specific in
nature, such as, the interactions of l-thyroxine with thy-
roxine-binding globulin or the binding of corticosteroids
and sex hormones to steroid-binding globulins (200, 201).
This protein binding is of interest because it plays a role in
determining the final biological activity, metabolism, and
Fig. 10. Analysis of a blank plasma sample (A) and a plasma sample taken 1 h after intravenous administration of leucovorin (B) by a
coupled-column HPLC system using a column containing a BSA chiral stationary phase and a C18 reversed-phase analytical column.
Peak 1, (6S)-leucovorin; peak 2, (6R)-leucovorin; peak 4, (6R)-5-methyltetrahydrofolate. Reproduced with permission from Silan et al. (156).
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elimination of many drugs and hormones. In addition, the
competition between drugs or between drugs and endog-
enous compounds (e.g., fatty acids or bilirubin) for pro-
tein binding sites can be an important source of drug-
drug or drug displacement interactions (196–199, 202).
Drug- and hormone-protein binding has been exam-
ined in affinity chromatography by the use of both
immobilized drugs and immobilized proteins, but pro-
tein-based columns currently are more common (195).
One advantage of using an immobilized protein column
for binding studies is the ability to reuse the same ligand
preparation for multiple experiments (e.g., up to 500-1000
injections per column in some HPLC studies) (203–205). It
is important in such experiments to first consider and
evaluate how effectively the immobilized protein models
the behavior of the same protein in its soluble form.
Fortunately, there is growing evidence that at least some
immobilized proteins, particularly HSA, can be used quite
successfully for the study of drug-protein interactions. For
example, it has been shown that association constants
measured by equilibrium dialysis for soluble HSA with R-
and S-warfarin or l-tryptophan (i.e., solutes that interact
with one of the two major binding regions of HSA) are in
close agreement with values determined using immobi-
lized HSA columns (206–208). It has also been found that
displacement phenomena and allosteric interactions ob-
served for HSA columns are representative of behavior
noted for HSA in solution (208–213).
zonal elution studies
The method of zonal elution is the technique that has been
used most frequently to study the binding of drugs and
other solutes on immobilized protein columns (193, 214).
This generally is done by injecting a small sample of the
drug or solute of interest into the presence of buffer only
or a fixed concentration of a competing agent in the
mobile phase. Analysis of the results is performed by
determining how the elution time, or retention factor (k9,
also known as the capacity factor) of the injected solute
changes as a function of the concentration of the compet-
ing agent (Fig. 11). Alternatively, similar experiments can
be used to examine how various solvent conditions affect
drug-protein interactions (141, 207, 215–221) or to de-
velop quantitative structure-retention relationships that
describe these binding processes (222–224).
The most common application of zonal elution and
HPLC-based affinity chromatography in drug- and hor-
mone-protein studies has been in the examination of the
displacement of drugs and hormones from proteins by
other solutes (195, 225). Examples include the use of zonal
elution to examine the displacement of d,l-thyronine and
d,l-tryptophan from HSA by bilirubin or caprylate (226);
the competition of R/S-warfarin with racemic oxazepam,
lorazepam, and their hemisuccinate derivatives on an
HSA column (211); the direct or allosteric competition of
octanoic acid on immobilized HSA for the binding sites of
R/S-warfarin, phenylbutazone, tolbutamide, R/S-oxaze-
pam hemisuccinate, ketoprofen A/B, and suprofen A/B
(213); the competition of R-warfarin and l-tryptophan
with d-tryptophan (207) or l-thyroxine and related thy-
ronine compounds on HSA (203, 208); and the displace-
ment of R- and S-ibuprofen by one another at their
binding regions on HSA (227). The same technique has
been used to characterize the binding sites of nonsteroidal
antiinflammatory drugs on HSA (228) and the displace-
ment of nonsteroidal antiinflammatory drugs and benzo-
diazepines by phenylbutazone, R/S-ibuprofen, or 2,3,5-
triiodobenzoic acid from serum albumin columns (229).
This type of work can provide not only qualitative infor-
mation on binding and displacement, but also quantita-
tive information on the equilibrium constants for these
processes and retention mechanisms (203, 208, 213, 222, 224,
227–229). Information on the kinetics of these solute-
protein interactions can also be obtained if appropriate
Fig. 11. Typical chromatograms (top) and association equilibrium
constants (bottom) obtained by zonal elution studies examining the
competitive binding of thyroid hormones with site-specific probe com-
pounds for the warfarin and indole regions of HSA.
The chromatograms were obtained for the injection of R-warfarin into the
presence of mobile phases containing (left to right) 1.90, 0.97, 0.49, 0.24, or
0.0 mmol/L of L-reverse triiodothyronine. T4, thyroxine; T3, triiodothyronine; rT3,
reverse triiodothyronine; T0, thyronine. L and D in the table refer to the L- or
D-enantiomers of each compound. Reproduced with permission from Loun and
Hage (203).
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data are collected on the width and retention for solute
peaks under various flow-rate conditions, as demon-
strated recently for R- and S-warfarin (204) and d,l-
tryptophan (205) on HSA columns.
frontal analysis studies
The technique of “frontal analysis” or “breakthrough
analysis” is a second method that can be used in affinity
chromatography to study biological interactions (195). In
this method, a solution containing a known concentration
of the solute to be studied is applied continuously to an
affinity column. As the solute binds to the immobilized
ligand, the ligand becomes saturated and the amount of
solute eluting from the column gradually increases, form-
ing a characteristic breakthrough curve. If fast association
and dissociation kinetics are present in the system, then
the mean positions of the breakthrough curves can be
related to the concentration of applied solute, the amount
of ligand in the column, and the association equilibrium
constants for solute-ligand binding. Regarding systems of
clinical interest, frontal analysis and affinity chromatog-
raphy have been used to investigate the binding of HSA
to R- or S-warfarin (206, 208) and d- or l-tryptophan
(205, 207, 208, 213); to determine the binding capacities of
monomeric vs dimeric HSA for salicylic acid, warfarin,
phenylbutazone, mefenamic acid, sulfamethizole, and
sulfonylureas (230); and to examine the competition of
sulfamethizole with salicylic acid for HSA binding re-
gions (231). This same approach recently was used to
characterize the binding of chemically modified HSA to
various site-specific probe compounds (232). Although
frontal analysis generally requires more of a drug or
hormone for study than zonal elution, this technique does
tend to provide binding constants that are more precise
and accurate than those measured by zonal elution meth-
ods (195).
Future Trends and Developments
Although it is clear that affinity chromatography can be
used in a variety of ways within clinical chemistry, there
remains plenty of room for new growth and development
in this method. One trend that has always been present in
affinity chromatography has been the search for more
selective, robust, and/or reproducible ligands. The avail-
ability of such ligands will become particularly important
if affinity chromatography is to be accepted as a routine
method in clinical laboratories.
There are several likely candidates of alternative li-
gands that should be useful in clinical testing but that
have not yet been used for such applications. One exam-
ple is a group of ligands based on synthetic dyes, such as
triazine or triphenylmethane compounds, which are used
in a technique known as “dye-ligand affinity chromatog-
raphy”. Specific ligands used in this method include
Cibacron Blue F3G-A, Procion Blue MX-3G or MX-R,
Procion Red HE-3B, and Thymol Blue or Phenol Red
(2, 3). Although these compounds are all synthetic in
nature, they are still classified as affinity ligands because
they interact with the active sites of many proteins and
enzymes by mimicking the structure of the substrates,
cofactors, or binding agents for these biomolecules. For
example, Cibacron Blue F3G-A consists of a chlorotriazine
ring that has several side groups attached, one of which is
an anthraquinone that interacts with enzymes that have a
binding site for NAD1, NADP1, or ATP. Some advan-
tages of these dye ligands include their selectivity, repro-
ducibility, and ability to be produced in large quantities.
These properties have made them useful for the large-
scale purification of dehydrogenases, kinases, albumin,
a-fetoprotein, CoA-dependent enzymes, hydrolases, IgG,
lipoproteins, nucleases, polymerases, synthetases, and
transferases (2, 3, 233, 234). It probably is only a matter of
time until these dyes appear in affinity methods for the
quantification of similar proteins and enzymes in clinical
samples.
“Immobilized metal ion affinity chromatography”, also
known as “metal chelate affinity chromatography”, is
another method that has been widely used in purification
processes but that has not yet received much attention in
clinical testing. In this approach, the affinity ligand is a
metal ion that is complexed with an immobilized chelat-
ing agent. Iminodiacetic acid is the most common chelat-
ing agent used, but carboxymethylaspartic acid, tris-
carboxymethylethylenediamine, tris(2-aminoethyl)amine,
or dipicolylamine sometimes are also used. The metal
ions placed within these chelating groups are Cu21, Zn21,
Ni21, Co21, or Fe31. This method separates proteins and
peptides on the basis of interactions between certain
amino acid residues (such as histidine, tryptophan, or
cysteine) and the metal ions within the immobilized metal
chelate (235–237). Since its discovery, several peptides,
proteins, and amino acids have been purified commer-
cially by this method. Like dye-ligand affinity chromatog-
raphy, immobilized metal ion affinity chromatography is
quite selective and is based on ligands that can be made
reproducibly on a large scale, again making this approach
attractive for future work in clinical applications.
Two other types of ligands that may become important
in clinical testing by affinity chromatography are those
based on aptamers and molecular imprints. Aptamers are
polymers of nucleotides that have well-defined sequences
and three-dimensional structures. These are of current
interest in research because it has been shown that a large
number of aptamers can be generated randomly in an
oligonucleotide library and then those ligands that bind to
a given target solute can be enriched selectively for use in
applications such as affinity chromatography (238–240).
A molecular imprint is an affinity ligand that is actually
part of the surface or internal structure of the support
used in the affinity column. These are usually made by
combining the analyte of interest with a series of mono-
mers that contain side chains capable of forming various
interactions with the analyte. As these interactions take
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place, the monomers are fixed in position about the
analyte by polymerization. After polymerization has oc-
curred, the support is ground into a powder, the retained
analyte is released by the application of an appropriate
solvent, and the imprinted support is placed in a column
for use. In this way, an affinity support is created that has
known specificity and binding/elution properties
(241, 242). Some appealing characteristics of both aptam-
ers and molecular imprints are their ability to be custom-
designed for a given analyte, their stability over long-term
use, and their moderate-to-high selectivity (238–242).
However, more research and development in optimizing
the use and production of these ligands is still needed
before their full potential can be realized in clinical assays.
A second trend that is expected to continue in affinity
chromatography is the search for improved system de-
signs and formats that will give this technique greater
speed, selectivity, and higher sample throughput. This is
needed to make this approach competitive with more
common clinical methods, such as batch-mode immuno-
assays. One way of obtaining increased selectivity while
also increasing the number of solutes that are examined
per assay is by using affinity chromatography in combi-
nation with other analytical techniques. This can already
be seen in the growing popularity of the use of off-line
affinity extraction with HPLC or GC and the use of on-line
affinity extraction with HPLC. In the future, continued
progress probably will be made in the development of
such tandem methods, as well as in the further combina-
tion of on-line affinity extraction with GC (128) or CE
(129–131) and mass spectrometry (111, 243). As discussed
earlier, another approach for obtaining increased sample
throughput is to use an array of affinity columns in series
for the determination of a battery of clinical analytes (Fig.
5). Alternatively, a group of identical affinity columns
might be operated in parallel for determining the same
solute in multiple samples.
The applications described in this review clearly dem-
onstrate that affinity chromatography is an attractive
alternative to traditional methods for the selective quan-
tification and study of clinical samples. This combination
of the large number of ligands that are available for
affinity chromatography and the various operating for-
mats that can be used for direct or indirect solute deter-
mination allows the creation of an affinity system for
almost any compound of clinical interest. Affinity chro-
matography should become especially valuable to clinical
laboratories as greater importance is placed on more
specialized tests, such as the analysis of chiral drugs or the
examination of drug- and hormone-protein binding. In
the years to come, even more applications for this method
should appear in clinical chemistry, as workers in this
field become more familiar with affinity chromatogra-
phy and the information that it can provide on clinical
samples.
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